DelMar Pharmaceuticals (NASDAQ:DMPI) posted its quarterly earnings data on Tuesday. The company reported ($0.13) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.03), Fidelity Earnings reports.
NASDAQ:DMPI traded up $0.03 on Thursday, hitting $1.00. The stock had a trading volume of 1,200 shares, compared to its average volume of 470,239. The firm has a market cap of $22.81 million, a price-to-earnings ratio of -1.35 and a beta of 1.46. DelMar Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $1.01.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase III study for the treatment of recurrent glioblastoma multiforme.
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.